Education
About Us
Working with TipRanks
Follow Us
Vir Biotechnology (VIR)
NASDAQ:VIR
VIR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$6.56 - $14.45
Previous CloseN/A
Volume25.73M
Average Volume (3M)1.24M
Market Cap
$950.40M
Enterprise Value$132.28M
Total Cash (Recent Filing)$222.95M
Total Debt (Recent Filing)$97.89M
Price to Earnings (P/E)―
Beta0.66
Next Earnings
May 01, 2025EPS Estimate
-0.84Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.83
Shares Outstanding137,143,280
10 Day Avg. Volume1,385,839
30 Day Avg. Volume1,238,381
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)13.00
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market Cap0.14
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit1.80
Enterprise Value/Ebitda-0.25
Forecast
1Y Price Target
$32.00Price Target Upside361.76% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Vir Biotechnology News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsEnrollment commences in Ph3 ECLIPSE trial to bring chronic hepatitis delta therapy to market.
Financial PerformanceVir's disciplined financial management has extended its cash runway into mid-2027, with 2024 R&D and SG&A expenses down 30% and 32%, respectively, reflecting prudent capital allocation.
Regulatory ProgressRecent FDA Breakthrough and Fast Track designations, along with EMA PRIME and Orphan Drug status, support an accelerated approval pathway for Vir's HDV combination regimen.
Bears Say
Market ConcernsThere are concerns over the value-accretive potential from HBV phase 2 and HDV phase 3 trial updates, which could affect stock performance.
Stock PerformanceThe company's shares are expected to remain range-bound over the near-to-midterm due to concerns over the value-accretive potential from HBV phase 2 and HDV phase 3 trial updates.
---
Ownership Overview
15.16% Insiders
13.56% Mutual Funds
22.39% Other Institutional Investors
27.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VIR FAQ
What was Vir Biotechnology’s price range in the past 12 months?
Vir Biotechnology lowest stock price was $6.56 and its highest was $14.45 in the past 12 months.
What is Vir Biotechnology’s market cap?
Vir Biotechnology’s market cap is $950.40M.
When is Vir Biotechnology’s upcoming earnings report date?
Vir Biotechnology’s upcoming earnings report date is May 01, 2025 which is in 37 days.
How were Vir Biotechnology’s earnings last quarter?
Vir Biotechnology released its earnings results on Feb 26, 2025. The company reported -$0.76 earnings per share for the quarter, beating the consensus estimate of -$0.872 by $0.112.
Is Vir Biotechnology overvalued?
According to Wall Street analysts Vir Biotechnology’s price is currently Undervalued.
Does Vir Biotechnology pay dividends?
Vir Biotechnology does not currently pay dividends.
What is Vir Biotechnology’s EPS estimate?
Vir Biotechnology’s EPS estimate is -0.84.
How many shares outstanding does Vir Biotechnology have?
Vir Biotechnology has 137,143,280 shares outstanding.
What happened to Vir Biotechnology’s price movement after its last earnings report?
Vir Biotechnology reported an EPS of -$0.76 in its last earnings report, beating expectations of -$0.872. Following the earnings report the stock price went down -11.848%.
Which hedge fund is a major shareholder of Vir Biotechnology?
Currently, no hedge funds are holding shares in VIR
---
Vir Biotechnology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.00 (361.76% Upside)
$32.00 (361.76% Upside)
Blogger Sentiment
Bullish
VIR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $566.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 4.3%
Last 30 Days ▼ 4.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-31.31%
12-Months-Change
Fundamentals
Return on Equity
-38.09%
Trailing 12-Months
Asset Growth
-27.37%
Trailing 12-Months
Company Description
Vir Biotechnology
Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
---
VIR Company Deck
---
VIR Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
Vir Biotechnology reported a transformative year with significant advancements in their pipeline, particularly in the oncology and infectious disease sectors. The financial position is strong with improved cost management leading to a reduced net loss and a solid cash runway. However, the promising clinical results are from heavily pre-treated populations, and there is a reliance on partnerships for the hepatitis B program. Overall, the highlights and strategic advancements outweigh the challenges.Read More>---
VIR Stock 12 Month Forecast
Average Price Target
$32.00
▲(361.76% Upside)
Technical Analysis
Best Analysts Covering VIR
1 Year
1 Year Success Rate
5/21 ratings generated profit
1 Year Average Return
-14.53%
reiterated a buy rating 25 days ago
Copying Gena Wang's trades and holding each position for 1 Year would result in 23.81% of your transactions generating a profit, with an average return of -14.53% per trade.
---